bioAffinity Technologies ...
(BIAF)
undefined
undefined%
At close: undefined
0.95
2.05%
After-hours Jan 03, 2025, 05:01 PM EST
Company Description
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics.
The company offers CyPath lung, a diagnostic test, for early detection of lung cancer.
It also researches targeted therapies to treat cancer at the cellular level.
The company was founded in 2014 and is based in San Antonio, Texas.
bioAffinity Technologies Inc.
| Country | United States |
| IPO Date | Sep 1, 2022 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Maria Zannes J.D. |
Contact Details
Address: 22211 West Interstate 10 San Antonio, Texas United States | |
| Website | https://www.bioaffinitytech.com |
Stock Details
| Ticker Symbol | BIAF |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001712762 |
| CUSIP Number | 09076W109 |
| ISIN Number | US09076W1099 |
| Employer ID | 46-5211056 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Maria Zannes J.D. | Founder, President, Chief Executive Officer & Director |
| J. Michael Edwards CPA, M.B.A. | Chief Financial Officer & Principal Accounting Officer |
| Xavier T. Reveles M.S. | Chief Operating Officer |
| Dallas J. Coleman | Vice President of sales |
| Dr. William Bauta Ph.D. | Chief Science Officer |
| Julie Anne Overton | Director of Communications |
| Steven Girgenti | Founder & Executive Chairman of the Board |
| Timothy P. Zannes J.D. | Executive Vice President, Secretary & General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2024 | 8-K | Current Report |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 09, 2024 | 424B3 | Filing |
| Nov 27, 2024 | S-1 | Filing |
| Nov 22, 2024 | 424B3 | Filing |
| Nov 22, 2024 | 424B3 | Filing |
| Nov 22, 2024 | 424B3 | Filing |
| Nov 22, 2024 | DEF 14A | Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |